Efineptakin alfa
AssetAlso HYLEUKIN, NT-I7, hIL-7-hyFc
Long-acting interleukin-7 therapy intended to restore thymic function.
- Stage
- Phase 1
- Modality
- Protein or enzyme
- Target
- IL7R
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Thymic function
Phase 1, tolerancebio.com, 7 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Aging relevance2
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.